🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Jefferies Group’s FATE Holdings & Trades

First Buy
Q2 2026
Duration Held
2 Quarters
Largest Add
Q2 2026
+59,122 Shares
Current Position
95,600 Shares
$226,572 Value

Jefferies Group's FATE Position Overview

Jefferies Group (via Jefferies Financial Group Inc.) currently holds 95,600 shares of Fate Therapeutics, Inc. (FATE) worth $226,572, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 2 quarters.

Based on recent 13F filings, Jefferies Group has initiated a new position in FATE, representing a fresh investment thesis on this company. Largest addition occurred in Q3 2026, adding 36,478 shares.

Analysis based on 13F filings available since 2013 Q2

Jefferies Group's Fate Therapeutics (FATE) Holding Value Over Time

Track share changes against reported price movement

Quarterly Fate Therapeutics (FATE) Trades by Jefferies Group

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +36,478 Add 61.70% 95,600 $2.37
Q2 2026 +59,122 New Buy 59,122 $2.70

Jefferies Group's Fate Therapeutics Investment FAQs

Jefferies Group first purchased Fate Therapeutics, Inc. (FATE) in Q2 2026, acquiring 59,122 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Jefferies Group has held Fate Therapeutics, Inc. (FATE) for 2 quarters since Q2 2026.

Jefferies Group's largest addition to Fate Therapeutics, Inc. (FATE) was in Q2 2026, adding 59,122 shares worth $159,629.

According to the latest 13F filing for Q3 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 95,600 shares of Fate Therapeutics, Inc. (FATE), valued at approximately $226,572.

As of the Q3 2026 filing, Fate Therapeutics, Inc. (FATE) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.

Jefferies Group's peak holding in Fate Therapeutics, Inc. (FATE) was 95,600 shares, as reported at the end of Q3 2026.